| scholarly article | Q13442814 |
| P2093 | author name string | Santo Monte | |
| P2860 | cites work | The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18 | Q81301887 |
| Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation | Q81429334 | ||
| Pre-eclampsia | Q81446389 | ||
| First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery | Q81575462 | ||
| Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia | Q81920292 | ||
| A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound | Q82068160 | ||
| Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy | Q71664957 | ||
| Localisation of placenta growth factor (PIGF) in human term placenta | Q71779652 | ||
| Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction | Q73015033 | ||
| Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum | Q77785524 | ||
| Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia | Q77945374 | ||
| Elevated soluble adhesion molecules in women with pre-eclampsia. Do cytokines like tumour necrosis factor-alpha and interleukin-1beta cause endothelial activation | Q78202117 | ||
| Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences | Q79260245 | ||
| Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia | Q79398077 | ||
| First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia | Q79409207 | ||
| Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion | Q79685499 | ||
| Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia | Q79719767 | ||
| First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system | Q79719770 | ||
| First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome | Q79772135 | ||
| Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia | Q79823183 | ||
| Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia | Q79829262 | ||
| Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction | Q80140120 | ||
| Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy | Q80586036 | ||
| Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening | Q80602749 | ||
| beta-globin DNA in maternal plasma as a molecular marker of pre-eclampsia | Q80602764 | ||
| ADAM12s in maternal serum as a potential marker of pre-eclampsia | Q80673251 | ||
| ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy | Q80801699 | ||
| Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia | Q80812036 | ||
| Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein | Q22010697 | ||
| Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component | Q24294475 | ||
| A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo | Q24316824 | ||
| Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells | Q24337230 | ||
| CD105 is important for angiogenesis: evidence and potential applications | Q28207439 | ||
| Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: identification of a novel inducible inhibitor | Q28207689 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Functional analyses of placental protein 13/galectin-13 | Q28249207 | ||
| Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17) | Q28275001 | ||
| A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS | Q28584813 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| ADAMs: modulators of cell–cell and cell–matrix interactions | Q30311872 | ||
| Characterization of GMP-140 (P-selectin) as a circulating plasma protein | Q30988941 | ||
| Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. | Q33257880 | ||
| Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion | Q33316902 | ||
| Size fractionation of cell-free DNA in maternal plasma and its application in noninvasive detection of fetal single gene point mutations | Q33329574 | ||
| A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma | Q33361680 | ||
| Microparticle-associated P-selectin reflects platelet activation in preeclampsia | Q33374589 | ||
| PP13 mRNA expression in trophoblasts from preeclamptic placentas | Q33393566 | ||
| The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. | Q33755648 | ||
| Detection of the placental epigenetic signature of the maspin gene in maternal plasma. | Q34078379 | ||
| Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). | Q34104978 | ||
| Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. | Q34324823 | ||
| Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. | Q34326623 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction | Q34647428 | ||
| VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis | Q35299319 | ||
| Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury | Q35748031 | ||
| Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies | Q35764454 | ||
| Placental-related diseases of pregnancy: Involvement of oxidative stress and implications in human evolution | Q35810254 | ||
| P-selectin in haemostasis | Q35838444 | ||
| Circulating angiogenic factors in preeclampsia | Q36086665 | ||
| The P-selectin, tissue factor, coagulation triad | Q36230814 | ||
| Disturbances in placental immunology: ready for therapeutic interventions? | Q36494229 | ||
| Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia | Q36772545 | ||
| The role of the immune system in preeclampsia | Q36791219 | ||
| A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma | Q36984261 | ||
| Placental origins of preeclampsia: challenging the current hypothesis | Q37079631 | ||
| The two stage model of preeclampsia: variations on the theme | Q37187589 | ||
| First-trimester maternal serum PP13 in the risk assessment for preeclampsia. | Q37444801 | ||
| Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review | Q37665733 | ||
| Maternal serum ADAM12s as a marker of rare aneuploidies in the first or second trimester of pregnancy | Q40156313 | ||
| Characterization and partial purification of the insulin-like growth factor (IGF)-dependent IGF binding protein-4-specific protease from human fibroblast conditioned media | Q40960014 | ||
| Preeclampsia: an endothelial cell disorder | Q41281924 | ||
| Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta | Q41385756 | ||
| Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia | Q44017351 | ||
| Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. | Q44044678 | ||
| Folic acid supplementation in early second trimester and the risk of preeclampsia | Q44054579 | ||
| Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women | Q44876557 | ||
| A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia | Q45271925 | ||
| Characterization of the enzymatic specificity of the IGF-dependent insulin-like growth factor binding protein-4 (IGFBP-4) protease | Q46046302 | ||
| High levels of fetal erythroblasts and fetal extracellular DNA in the peripheral blood of a pregnant woman with idiopathic polyhydramnios: case report | Q46354245 | ||
| The long pentraxin PTX3 in human endometrium: regulation by steroids and trophoblast products | Q46874544 | ||
| Quantification of circulatory fetal DNA in the plasma of pregnant women | Q47761347 | ||
| Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. | Q47889241 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. | Q50106089 | ||
| Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma. | Q50762528 | ||
| Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. | Q50775910 | ||
| Molecular evidence of placental hypoxia in preeclampsia. | Q51975690 | ||
| Soluble endoglin as a second-trimester marker for preeclampsia. | Q53535438 | ||
| Pregnancy associated plasma protein-A is necessary for expeditious fracture healing in mice. | Q53568079 | ||
| Refined fluorescent STR quantification of cell-free fetal DNA during pregnancy in physiological and Down syndrome fetuses. | Q54538251 | ||
| Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. | Q54574187 | ||
| High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. | Q54648888 | ||
| THE LEVELS OF CIRCULATORY FETAL DNA IN MATERNAL PLASMA ARE ELEVATED PRIOR TO THE ONSET OF PREECLAMPSIA | Q56001888 | ||
| Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction | Q56942827 | ||
| Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation | Q56994317 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Quantitative aberrations of hypermethylatedRASSF1A gene sequences in maternal plasma in pre-eclampsia | Q58029335 | ||
| Vascular endothelial growth factor but not placental growth factor promotes trophoblast syncytialization in vitro | Q59367182 | ||
| Plasma and Tissue Expression of the Long Pentraxin 3 During Normal Pregnancy and Preeclampsia | Q60609634 | ||
| Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction | Q60947387 | ||
| A Vascular Endothelial Growth Factor Antagonist Is Produced by the Human Placenta and Released into the Maternal Circulation1 | Q61479346 | ||
| Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age | Q61845341 | ||
| Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia | Q61865449 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 69-77 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Journal of prenatal medicine | Q27723772 |
| P1476 | title | Biochemical markers for prediction of preclampsia: review of the literature | |
| P478 | volume | 5 |
| Q94369539 | Book Review |
| Q91846514 | Development of a new methylation-based fetal fraction estimation assay using multiplex ddPCR |
| Q89863319 | Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study |
| Q37502706 | The complement cascade and renal disease. |
Search more.